Alpha 2.0
Login Register
» Authors » N U Lin

N U Lin

Explore the profile of N U Lin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 1111
Followers 0
Related Specialties
Oncology
Molecular Biology
Endocrinology
Top 10 Co-Authors
E P Winer
I E Krop
S M Tolaney
J J Zhao
H J Burstein
P Liu
P Tarantino
T M Roberts
M E Hughes
C L Arteaga
Published In
Ann Oncol
ESMO Open
Oncogene
J Clin Endocrinol Metab
Breast Cancer Res Treat
Affiliations
Soon will be listed here.
Recent Articles
1.
Correction: PIK3CA- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling
Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, et al.
Oncogene . 2025 Jan; 44(7):478-479. PMID: 39890968
No abstract available.
2.
Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2
Qiu X, Tarantino P, Li R, Grinshpun A, Gupta H, Hughes M, et al.
ESMO Open . 2025 Jan; 10(2):104111. PMID: 39826477
Background: The approval of trastuzumab deruxtecan has prompted the subgrouping of human epidermal growth factor receptor 2-negative (HER2-) breast cancers (BCs) to HER2 0 and HER2 low on the basis...
3.
Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis
Bartsch R, Perez-Garcia J, Furtner J, Berghoff A, Marhold M, Starzer A, et al.
ESMO Open . 2025 Jan; 10(1):104092. PMID: 39754978
Background: Brain metastases (BMs) are common in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, increasing morbidity and mortality. Systemic therapy for BMs can be effective, with the...
4.
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆
Raghavendra A, Zakon D, Jin Q, Strahan A, Grimm M, Hughes M, et al.
ESMO Open . 2024 Nov; 9(11):103973. PMID: 39500139
Background: The impact of human epidermal growth factor receptor 2 (HER2) expression determined by immunohistochemistry (IHC) on outcomes in early-stage triple-negative breast cancer (eTNBC) is unclear. Using a large, multi-institutional...
5.
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022
Freedman R, Heiling H, Li T, Trapani D, Tayob N, Smith K, et al.
Ann Oncol . 2024 Jul; 35(11):993-1002. PMID: 38977064
Background: Treatment options for human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases (BCBMs) remain limited. We previously reported central nervous system (CNS) activity for neratinib and neratinib-capecitabine....
6.
Antibody-drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?
Sammons S, Lin N
ESMO Open . 2024 May; 9(5):102990. PMID: 38796286
No abstract available.
7.
Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?
Giordano A, Lin N, Tolaney S, Mayer E
Ann Oncol . 2023 Nov; 35(1):10-14. PMID: 37952893
No abstract available.
8.
Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases
Lin N
ESMO Open . 2022 Oct; 7(6):100596. PMID: 36228333
No abstract available.
9.
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
Tarantino P, Burstein H, Lin N, Krop I, Winer E, Schnitt S, et al.
Ann Oncol . 2021 Dec; 33(3):234-238. PMID: 34942341
No abstract available.
10.
How we treat HER2-positive brain metastases
Stavrou E, Winer E, Lin N
ESMO Open . 2021 Sep; 6(5):100256. PMID: 34482180
Overexpression of the human epidermal growth factor 2 (HER2)/neu glycoprotein receptor in breast cancer is associated with increased risk of brain metastases, especially in patients with advanced disease. Improvements in...